Ronald K. Lloyd - May 7, 2021 Form 4 Insider Report for AZIYO BIOLOGICS, INC. (ELUT)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Ronald Lloyd
Stock symbol: ELUT
Transactions as of: May 7, 2021
Transactions value $: $100,643
Form type: 4
Date filed: 5/11/2021, 04:40 PM
Next filing: Mar 10, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELUT	Class A Common Stock	Purchase	$83.9K	+7.2K	+49.35%	$11.65^*	21.8K	May 7, 2021	Direct	F1
transaction	ELUT	Class A Common Stock	Purchase	$16.8K	+1.37K	+6.28%	$12.28^*	23.2K	May 7, 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.20 to $12.18. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.39. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.20 to $12.18. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.39. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.